- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03729596
MGC018 With or Without MGA012 in Advanced Solid Tumors
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti-B7-H3 Antibody Drug Conjugate) Alone and in Combination With MGA012 (Anti-PD-1 Antibody) in Patients With Advanced Solid Tumors
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This Phase 1/2 study will characterize safety, dose-limiting toxicities (DLTs), and maximum tolerated/administered dose (MTD/MAD) and anti-tumor activity for vobramitamab duocarmazine as monotherapy (Module A) in patients with advanced solid tumors. Patients with solid tumors will be enrolled in the Dose Escalation Phase; Cohort Expansion will include metastatic castrate-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), squamous cell carcinoma of the head and neck (SCCHN), and melanoma. Patients who do not experience unacceptable toxicity or meet criteria for permanent discontinuation may undergo additional cycles for up to two years. Patients in Cohort Expansion will be followed for survival every 3 months for 2 years following last dose.
Module B, vobramitamab duocarmazine in combination with retifanlimab will not enroll.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Darlinghurst, Australia, 2010
- St Vincent's Health Network (Kinghorn Cancer Centre)
-
Heidelberg, Australia, 3084
- Austin Health - Olivia Newton John Cancer Center
-
Waratah, Australia, 2298
- Calvary Mater Newcastle
-
Woolloongabba, Australia, 4105
- The University of Queensland - Princess Alexandra Hospital (PAH)
-
-
-
-
-
Krakow, Poland, 31-501
- Samodzielny Publiczny Zakład Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie Oddział Kliniczny Onkologii
-
Poznań, Poland, 60-693
- Med-Polonia Sp. z o.o.
-
Warsaw, Poland, 02-781
- Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy Oddział Badań Wczesnych Faz
-
Warszawa, Poland, 01-748
- Magodent Sp. z o.o. Szpital Elbląska Oddział Onkologii Klinicznej/ Chemioterapii
-
-
-
-
-
Barcelona, Spain, 08035
- Hospital Universitario Vall d'Hebron
-
Barcelona, Spain
- Institut Català D'Oncologia - Hospital Universitari Germans Trias I Pujol
-
Madrid, Spain, 28034
- Hospital Ruber Internacional
-
Madrid, Spain, 20850
- Hospital Universitario HM Sanchinarro
-
-
-
-
California
-
Santa Monica, California, United States, 90404
- UCLA Department of Medicine - Hematology/Oncology
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20016
- Sibley Memorial Hospital
-
-
Maryland
-
Baltimore, Maryland, United States, 21231
- The Johns Hopkins Kimmel Cancer Center
-
-
Michigan
-
Grand Rapids, Michigan, United States, 49546
- START Midwest
-
-
Nebraska
-
Omaha, Nebraska, United States, 68114
- Nebraska Methodist Hospital
-
-
Nevada
-
Las Vegas, Nevada, United States, 89169
- Comprehensive Cancer Centers of Nevada
-
-
North Carolina
-
Huntersville, North Carolina, United States, 28078
- Carolina BioOncology Institute
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- Inova Schar Cancer Institute
-
Fairfax, Virginia, United States, 22031
- Virginia Cancer Specialist
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Tissue specimen available for retrospective analysis of B7-H3 and PD-L1 expression.
- Eastern Cooperative Oncology Group performance status of ≤2
- Life expectancy ≥ 12 weeks for dose escalation phase and ≥ 24 weeks for cohort expansion phase
- Measurable disease. Prostate cancer patients with bone only disease are eligible.
- Acceptable laboratory parameters and adequate organ reserve.
- Dose Escalation Phase: Patients with histologically proven, unresectable, locally advanced or metastatic solid tumors for whom no therapy with demonstrated clinical benefit is available.
Module A Cohort Expansion:
- mCRPC that has progressed with one prior line of chemotherapy for metastatic disease and no more than two prior lines of anti-hormonal therapy.
- NSCLC: metastatic disease after standard cytotoxic, targeted, and biologic or checkpoint inhibitor therapy. No more than 2 prior lines of chemotherapy.
- TNBC: Locally advance or metastatic disease that has progressed following at least one systemic therapy.
- SCCHN that has progressed during or following at least one systemic therapy for metastatic or recurrent unresectable disease. No more than 2 prior lines of chemotherapy.
- Melanoma that has progressed during or following at least one systemic treatment for unresectable locally advanced or metastatic disease. Patients who are intolerant of or refused standard therapy are eligible.
Exclusion Criteria:
- Patients with history of prior central nervous system (CNS) metastasis must have been treated, be asymptomatic, and not have concurrent treatment for CNS disease, progression of CNS metastases on MRI, CT or PET within 6 months, or history of leptomeningeal disease or cord compression at the time of enrollment.
- Prior treatment with B7-H3 targeted agents for cancer.
- Treatment with systemic cancer therapy, biologic agents, or anti-hormonal therapy (mCRPC) within 4 weeks, prior small molecule targeted or kinase inhibitors within 14 days or 5 half-lives, prior radioligand within 6 months
- Clinically significant cardiovascular disease.
- Clinically significant pulmonary compromise or requirement for supplemental oxygen.
- History of clinically-significant cardiovascular disease, including but not limited to pericarditis or pericardial effusion.
- Active viral (including confirmed or presumed COVID-19), bacterial, or systemic fungal infection requiring parenteral treatment within 7 days of first study drug administration.
- Known history of hepatitis B or C infection or known positive test for hepatitis B surface antigen or core antigen, or hepatitis C polymerase chain reaction.
- Known positive testing for human immunodeficiency virus or history of acquired immune deficiency syndrome.
- Major trauma or major surgery within 4 weeks of first study drug administration.
- Clinically significant venous insufficiency.
- > Grade 1 peripheral neuropathy.
- Evidence of pleural effusion.
- Evidence of ascites.
- Serum testosterone >50 ng/dl or >1.7 nmol/L in mCRPC in Module A Cohort Expansion Phase
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1
0.5 mg/kg IV every 3 weeks
|
Anti-B7H3 antibody drug conjugate
Other Names:
|
Experimental: Cohort 2
1.0 mg/kg IV every 3 weeks
|
Anti-B7H3 antibody drug conjugate
Other Names:
|
Experimental: Cohort 3
2.0 mg/kg IV every 3 weeks
|
Anti-B7H3 antibody drug conjugate
Other Names:
|
Experimental: Cohort 4
3.0 mg/kg IV every 3 weeks
|
Anti-B7H3 antibody drug conjugate
Other Names:
|
Experimental: Cohort 5
4.0 mg/kg IV every 3 weeks
|
Anti-B7H3 antibody drug conjugate
Other Names:
|
Experimental: mCRPC expansion
3.0 mg/kg IV every 3 weeks
|
Anti-B7H3 antibody drug conjugate
Other Names:
|
Experimental: NSCLC expansion
3.0 mg/kg IV every 3 weeks
|
Anti-B7H3 antibody drug conjugate
Other Names:
|
Experimental: TNBC expansion
3.0 mg/kg IV every 3 weeks
|
Anti-B7H3 antibody drug conjugate
Other Names:
|
Experimental: Melanoma expansion
3.0 mg/kg IV every 3 weeks
|
Anti-B7H3 antibody drug conjugate
Other Names:
|
Experimental: SCCHN expansion
3.0 mg/kg IV every 3 weeks
|
Anti-B7H3 antibody drug conjugate
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients with Adverse Events of vobramitamab duocarmazine as assessed by CTCAE v4.03
Time Frame: Throughout the study up to 24 months
|
Safety is based on evaluation of adverse events (AEs) and serious adverse events (SAEs) from the time of study drug administration through the End of Study visit.
|
Throughout the study up to 24 months
|
Number of patients with dose limiting toxicities (DLT)
Time Frame: up to 42 days from first dose
|
Maximum tolerated or maximum administered dose of vobramitamab duocarmazine
|
up to 42 days from first dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Best overall response (BOR) of vobramitamab duocarmazine
Time Frame: Throughout the study for up to 24 months
|
The best response recorded from the start of the study treatment until the end of treatment with vobramitamab duocarmazine, taking into account any requirement for confirmation of response.
|
Throughout the study for up to 24 months
|
Objective response rate (ORR) of vobramitamab duocarmazine
Time Frame: Efficacy evaluations every 9 weeks throughout the study for up to 24 months
|
The percentage of participants who achieve a complete response (CR or partial response (PR) to treatment with vobramitamab duocarmazine
|
Efficacy evaluations every 9 weeks throughout the study for up to 24 months
|
Progression free survival (PFS) of vobramitamab duocarmazine
Time Frame: Every 9 weeks for up to 24 months
|
Efficacy assessed as the first dose date to the date of first documented progression using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), or death from any cause, whichever occurs first.
|
Every 9 weeks for up to 24 months
|
Duration of response (DoR) of vobramitamab duocarmazine
Time Frame: Throughout the study for up to 48 months
|
Efficacy assessed as the time from the date of initial objective response to the date of first documented progression RECIST v1.1, or the date of death from any cause, whichever occurs first.
|
Throughout the study for up to 48 months
|
Overall survival (OS) of vobramitamab duocarmazine
Time Frame: Every 9 weeks for up to 24 months
|
Efficacy assessed as the time from the first dose date to the date of death from any cause.
|
Every 9 weeks for up to 24 months
|
PSA response rate
Time Frame: Every 3 weeks up to 24 months
|
Percent of prostate cancer patients with at least 50% reduction in prostate-specific antigen (PSA) with confirmation at least 3 weeks later
|
Every 3 weeks up to 24 months
|
Best PSA response
Time Frame: Every 3 weeks up to 24 months
|
For prostate cancer patients, the greatest change from baseline in PSA.
|
Every 3 weeks up to 24 months
|
CL
Time Frame: Cycle 1 (each cycle is 21 days) and Cycle 2: Predose, end of infusion (EOI), 1, 4, 24, 72 hours post-infusion and predose on Days 8, 15 and 22; Predose and EOI samples collected at Day 1 Cycle 3 and afterwards for up to 24 months
|
Total body clearance of the drug from plasma of vobramitamab duocarmazine and vobramitamab duocarmazine+retifanlimab
|
Cycle 1 (each cycle is 21 days) and Cycle 2: Predose, end of infusion (EOI), 1, 4, 24, 72 hours post-infusion and predose on Days 8, 15 and 22; Predose and EOI samples collected at Day 1 Cycle 3 and afterwards for up to 24 months
|
Area under the curve
Time Frame: Cycle 1 (each cycle is 21 days) and Cycle 2: Predose, end of infusion (EOI), 1, 4, 24, 72 hours post-infusion and predose on Days 8, 15 and 22; Predose and EOI samples collected at Day 1 Cycle 3 and afterwards for up to 24 months
|
Area under the plasma concentration versus time curve of vobramitamab duocarmazine
|
Cycle 1 (each cycle is 21 days) and Cycle 2: Predose, end of infusion (EOI), 1, 4, 24, 72 hours post-infusion and predose on Days 8, 15 and 22; Predose and EOI samples collected at Day 1 Cycle 3 and afterwards for up to 24 months
|
Cmax
Time Frame: Cycle 1 (each cycle is 21 days) and Cycle 2: Predose, end of infusion (EOI), 1, 4, 24, 72 hours post-infusion and predose on Days 8, 15 and 22; Predose and EOI samples collected at Day 1 Cycle 3 and afterwards for up to 24 months
|
Maximum Plasma Concentration of vobramitamab duocarmazine
|
Cycle 1 (each cycle is 21 days) and Cycle 2: Predose, end of infusion (EOI), 1, 4, 24, 72 hours post-infusion and predose on Days 8, 15 and 22; Predose and EOI samples collected at Day 1 Cycle 3 and afterwards for up to 24 months
|
Tmax
Time Frame: Cycle 1 (each cycle is 21 days) and Cycle 2: Predose, end of infusion (EOI), 1, 4, 24, 72 hours post-infusion and predose on Days 8, 15 and 22; Predose and EOI samples collected at Day 1 Cycle 3 and afterwards for up to 24 months
|
Time to reach maximum (peak) plasma concentration of vobramitamab duocarmazine
|
Cycle 1 (each cycle is 21 days) and Cycle 2: Predose, end of infusion (EOI), 1, 4, 24, 72 hours post-infusion and predose on Days 8, 15 and 22; Predose and EOI samples collected at Day 1 Cycle 3 and afterwards for up to 24 months
|
Ctrough
Time Frame: Cycle 1 (each cycle is 21 days) and Cycle 2: Predose, end of infusion (EOI), 1, 4, 24, 72 hours post-infusion and predose on Days 8, 15 and 22; Predose and EOI samples collected at Day 1 Cycle 3 and afterwards for up to 24 months
|
Trough plasma concentration of vobramitamab duocarmazine
|
Cycle 1 (each cycle is 21 days) and Cycle 2: Predose, end of infusion (EOI), 1, 4, 24, 72 hours post-infusion and predose on Days 8, 15 and 22; Predose and EOI samples collected at Day 1 Cycle 3 and afterwards for up to 24 months
|
Vss
Time Frame: Cycle 1 (each cycle is 21 days) and Cycle 2: Predose, end of infusion (EOI), 1, 4, 24, 72 hours post-infusion and predose on Days 8, 15 and 22; Predose and EOI samples collected at Day 1 Cycle 3 and afterwards for up to 24 months
|
Apparent volume of distribution at steady state of vobramitamab duocarmazine
|
Cycle 1 (each cycle is 21 days) and Cycle 2: Predose, end of infusion (EOI), 1, 4, 24, 72 hours post-infusion and predose on Days 8, 15 and 22; Predose and EOI samples collected at Day 1 Cycle 3 and afterwards for up to 24 months
|
t1/2
Time Frame: Cycle 1 (each cycle is 21 days) and Cycle 2: Predose, end of infusion (EOI), 1, 4, 24, 72 hours post-infusion and predose on Days 8, 15 and 22; Predose and EOI samples collected at Day 1 Cycle 3 and afterwards for up to 24 months .
|
Terminal half life of vobramitamab duocarmazine
|
Cycle 1 (each cycle is 21 days) and Cycle 2: Predose, end of infusion (EOI), 1, 4, 24, 72 hours post-infusion and predose on Days 8, 15 and 22; Predose and EOI samples collected at Day 1 Cycle 3 and afterwards for up to 24 months .
|
Immunogenicity
Time Frame: Every 3 weeks through end of treatment, up to 24 months
|
Percent of patients with anti-drug antibodies against vobramitamab duocarmazine
|
Every 3 weeks through end of treatment, up to 24 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Ashley Ward, M.D., MacroGenics
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CP-MGC018-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Melanoma
-
H. Lee Moffitt Cancer Center and Research InstituteTurnstone Biologics, Corp.RecruitingMetastatic Melanoma | Conjunctival Melanoma | Ocular Melanoma | Unresectable Melanoma | Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Iris Melanoma | Acral Melanoma | Non-Cutaneous MelanomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Mucosal Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IA Melanoma | Stage IB Melanoma | Stage IIA MelanomaUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); University of VirginiaCompletedStage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage III Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma | Stage 0 Skin Melanoma | Stage I Skin Melanoma | Stage II Skin MelanomaUnited States
-
MelanomaPRO, RussiaRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma, Stage II | Melanoma, Uveal | Melanoma in Situ | Melanoma, OcularRussian Federation
-
National Cancer Institute (NCI)CompletedStage IV Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIB Melanoma | Stage IIC MelanomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IIA MelanomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); National Comprehensive Cancer NetworkTerminatedRecurrent Melanoma | Stage IV Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIIA Intraocular Melanoma | Stage IIIB Intraocular Melanoma | Stage...United States
-
Emory UniversityGenentech, Inc.Active, not recruitingStage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Unresectable Melanoma | Stage III Melanoma | Stage IIIA Skin Melanoma | Cutaneous Melanoma, Stage III | Cutaneous Melanoma, Stage IVUnited States
-
BiocadRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma Metastatic | Melanoma Unresectable | Melanoma AdvancedIndia, Russian Federation, Belarus
Clinical Trials on vobramitamab duocarmazine
-
MacroGenicsActive, not recruitingMelanoma | Non-small Cell Lung Cancer | Small-cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Anal Cancer | Malignant Melanoma | Non-small Cell Carcinoma | Oral Squamous Cell Carcinoma | Small Cell Carcinoma | Laryngeal Squamous Cell Carcinoma | Carcinoma, Squamous Cell of Head and Neck | Castration-Resistant... and other conditionsSpain, Australia, United States, Korea, Republic of, France, United Kingdom, Italy, Belgium, Poland
-
MacroGenicsRecruitingRenal Cell Carcinoma | Advanced Solid Tumor | Epithelial Ovarian Cancer | Hepatocellular Cancer | Malignant Melanoma | Pancreatic Ductal Carcinoma | Castration-Resistant Prostatic CancerUnited States
-
QuantumLeap Healthcare CollaborativeByondis B.V.WithdrawnOvarian Cancer | Metastatic Cancer | Metastatic Breast Cancer | Bladder Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Gastroesophageal Adenocarcinoma | Ovarian Carcinoma | HER2-positive Gastric Cancer | Metastatic Gastrointestinal Carcinoid Tumor | HER2-positive Metastatic Breast... and other conditionsUnited States
-
Byondis B.V.CompletedEndometrial CancerKorea, Republic of, Singapore, Russian Federation, Ukraine, United States, Poland, Serbia
-
Byondis B.V.CompletedSolid TumorUnited Kingdom, Belgium, Netherlands
-
Byondis B.V.CompletedMetastatic Breast CancerFrance, Belgium, Spain
-
Byondis B.V.CompletedMetastatic Breast CancerFrance, United States, United Kingdom, Belgium, Spain, Italy, Singapore, Denmark, Sweden, Canada, Netherlands
-
QuantumLeap Healthcare CollaborativeRecruitingBreast Cancer | Breast Neoplasms | Breast Tumors | HER2-positive Breast Cancer | Angiosarcoma | Locally Advanced Breast Cancer | HER2-negative Breast Cancer | TNBC - Triple-Negative Breast Cancer | Hormone Receptor Positive Tumor | Hormone Receptor Negative Tumor | Early-stage Breast CancerUnited States